{"count": 17, "results": [{"_id": "39215174", "pmid": 39215174, "title": "Metformin treatment for fragile X syndrome.", "journal": "Lab Anim (NY)", "authors": ["Le Bras A"], "date": "2024-09-01T00:00:00Z", "doi": "10.1038/s41684-024-01431-1", "meta_date_publication": "2024 Sep", "meta_volume": "53", "meta_issue": "9", "meta_pages": "218", "score": 50284.336, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ treatment for @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@fragile X syndrome@@@.", "citations": {"NLM": "Le Bras A. Metformin treatment for fragile X syndrome. Lab Anim (NY). 2024 Sep;53(9):218. PMID: 39215174", "BibTeX": "@article{39215174, title={Metformin treatment for fragile X syndrome.}, author={Le Bras A}, journal={Lab Anim (NY)}, volume={53}, number={9}, pages={218}}"}}, {"_id": "33757860", "pmid": 33757860, "title": "The safety and efficacy of metformin in fragile X syndrome: An open-label study.", "journal": "Prog Neuropsychopharmacol Biol Psychiatry", "authors": ["Proteau-Lemieux M", "Lacroix A", "Galarneau L", "Corbin F", "Lepage JF", "Çaku A"], "date": "2021-08-30T00:00:00Z", "doi": "10.1016/j.pnpbp.2021.110307", "meta_date_publication": "2021 Aug 30", "meta_volume": "110", "meta_issue": "", "meta_pages": "110307", "score": 50273.582, "text_hl": "The safety and efficacy of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@fragile X syndrome@@@: An open-label study.", "citations": {"NLM": "Proteau-Lemieux M, Lacroix A, Galarneau L, Corbin F, Lepage JF, Çaku A. The safety and efficacy of metformin in fragile X syndrome: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2021 Aug 30;110():110307. PMID: 33757860", "BibTeX": "@article{33757860, title={The safety and efficacy of metformin in fragile X syndrome: An open-label study.}, author={Proteau-Lemieux M and Lacroix A and Galarneau L and Corbin F and Lepage JF and Çaku A}, journal={Prog Neuropsychopharmacol Biol Psychiatry}, volume={110}, pages={110307}}"}}, {"_id": "32531912", "pmid": 32531912, "pmcid": "PMC7349631", "title": "Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome", "journal": "Brain Sci", "authors": ["Jasoliya M", "Bowling H", "Petrasic IC", "Durbin-Johnson B", "Klann E", "Bhattacharya A", "Hagerman R", "Tassone F"], "date": "2020-06-10T00:00:00Z", "doi": "10.3390/brainsci10060361", "meta_date_publication": "2020 Jun 10", "meta_volume": "10", "meta_issue": "6", "meta_pages": "", "score": 50271.293, "text_hl": "Blood-Based Biomarkers Predictive of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ Target Engagement in @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@Fragile X Syndrome@@@", "citations": {"NLM": "Jasoliya M, Bowling H, Petrasic IC, Durbin-Johnson B, Klann E, Bhattacharya A, Hagerman R, Tassone F. Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome Brain Sci. 2020 Jun 10;10(6):. PMID: 32531912", "BibTeX": "@article{32531912, title={Blood-Based Biomarkers Predictive of Metformin Target Engagement in Fragile X Syndrome}, author={Jasoliya M and Bowling H and Petrasic IC and Durbin-Johnson B and Klann E and Bhattacharya A and Hagerman R and Tassone F}, journal={Brain Sci}, volume={10}, number={6}}"}}, {"_id": "35955427", "pmid": 35955427, "pmcid": "PMC9368983", "title": "Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders", "journal": "Int J Mol Sci", "authors": ["Li N", "Zhou T", "Fei E"], "date": "2022-07-27T00:00:00Z", "doi": "10.3390/ijms23158281", "meta_date_publication": "2022 Jul 27", "meta_volume": "23", "meta_issue": "15", "meta_pages": "", "score": 50270.61, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in a drosophila @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@FXS@@@ model rescued long-term @DISEASE_Memory_Disorders @DISEASE_MESH:D008569 @@@memory defects@@@ and improved olfactory learning. ", "citations": {"NLM": "Li N, Zhou T, Fei E. Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders Int J Mol Sci. 2022 Jul 27;23(15):. PMID: 35955427", "BibTeX": "@article{35955427, title={Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders}, author={Li N and Zhou T and Fei E}, journal={Int J Mol Sci}, volume={23}, number={15}}"}}, {"_id": "36928853", "pmid": 36928853, "title": "Targeted Treatments for Fragile X Syndrome.", "journal": "Adv Neurobiol", "authors": ["Johnson D", "Clark C", "Hagerman R"], "date": "2023-01-01T00:00:00Z", "doi": "10.1007/978-3-031-21054-9_10", "meta_date_publication": "2023", "meta_volume": "30", "meta_issue": "", "meta_pages": "225-253", "score": 50267.35, "text_hl": "Targeted Treatments for @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@Fragile X Syndrome@@@.", "citations": {"NLM": "Johnson D, Clark C, Hagerman R. Targeted Treatments for Fragile X Syndrome. Adv Neurobiol. 2023;30():225-253. PMID: 36928853", "BibTeX": "@article{36928853, title={Targeted Treatments for Fragile X Syndrome.}, author={Johnson D and Clark C and Hagerman R}, journal={Adv Neurobiol}, volume={30}, pages={225-253}}"}}, {"_id": "38385885", "pmid": 38385885, "title": "State-of-the-art therapies for fragile X syndrome.", "journal": "Dev Med Child Neurol", "authors": ["Protic D", "Hagerman R"], "date": "2024-02-22T00:00:00Z", "doi": "10.1111/dmcn.15885", "meta_date_publication": "2024 Feb 22", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50264.79, "text_hl": "A combination of non-pharmacological therapies and pharmacotherapy is currently the most effective treatment for @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@FXS@@@. Currently, several targeted treatments, such as @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, @CHEMICAL_Sertraline @CHEMICAL_MESH:D020280 @@@sertraline@@@, and @CHEMICAL_Cannabidiol @CHEMICAL_MESH:D002185 @@@cannabidiol@@@, can be used by clinicians to treat @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@FXS@@@. ", "citations": {"NLM": "Protic D, Hagerman R. State-of-the-art therapies for fragile X syndrome. Dev Med Child Neurol. 2024 Feb 22;():. PMID: 38385885", "BibTeX": "@article{38385885, title={State-of-the-art therapies for fragile X syndrome.}, author={Protic D and Hagerman R}, journal={Dev Med Child Neurol}}"}}, {"_id": "37286070", "pmid": 37286070, "title": "Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model.", "journal": "Neurosci Lett", "authors": ["Takeda R", "Ishii R", "Parvin S", "Shiozawa A", "Nogi T", "Sasaki Y"], "date": "2023-06-05T00:00:00Z", "doi": "10.1016/j.neulet.2023.137317", "meta_date_publication": "2023 Jun 5", "meta_volume": "810", "meta_issue": "", "meta_pages": "137317", "score": 50258.73, "text_hl": "These results suggest that @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ rescues both postsynaptic and presynaptic phenotypes by inhibiting excess translation in @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@FXS@@@ neurons.", "citations": {"NLM": "Takeda R, Ishii R, Parvin S, Shiozawa A, Nogi T, Sasaki Y. Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model. Neurosci Lett. 2023 Jun 5;810():137317. PMID: 37286070", "BibTeX": "@article{37286070, title={Novel presynaptic assay system revealed that metformin ameliorates exaggerated synaptic release and Munc18-1 accumulation in presynapses of neurons from Fragile X syndrome mouse model.}, author={Takeda R and Ishii R and Parvin S and Shiozawa A and Nogi T and Sasaki Y}, journal={Neurosci Lett}, volume={810}, pages={137317}}"}}, {"_id": "39223257", "pmid": 39223257, "title": "Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome.", "journal": "Neuropsychopharmacology", "authors": ["Ferraguto C", "Piquemal-Lagoueillat M", "Lemaire V", "Moreau MM", "Trazzi S", "Uguagliati B", "Ciani E", "Bertrand SS", "Louette E", "Bontempi B", "Pietropaolo S"], "date": "2024-09-02T00:00:00Z", "doi": "10.1038/s41386-024-01956-6", "meta_date_publication": "2024 Sep 2", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50247.832, "text_hl": "@CHEMICAL_Chlorzoxazone @CHEMICAL_MESH:D002753 @@@Chlorzoxazone@@@ was more efficacious in alleviating these phenotypes than @CHEMICAL_gaboxadol @CHEMICAL_MESH:C015542 @@@gaboxadol@@@ and @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, two repurposed treatments for @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@FXS@@@ that do not target BKCa channels. ", "citations": {"NLM": "Ferraguto C, Piquemal-Lagoueillat M, Lemaire V, Moreau MM, Trazzi S, Uguagliati B, Ciani E, Bertrand SS, Louette E, Bontempi B, Pietropaolo S. Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome. Neuropsychopharmacology. 2024 Sep 2;():. PMID: 39223257", "BibTeX": "@article{39223257, title={Therapeutic efficacy of the BKCa channel opener chlorzoxazone in a mouse model of Fragile X syndrome.}, author={Ferraguto C and Piquemal-Lagoueillat M and Lemaire V and Moreau MM and Trazzi S and Uguagliati B and Ciani E and Bertrand SS and Louette E and Bontempi B and Pietropaolo S}, journal={Neuropsychopharmacology}}"}}, {"_id": "28436599", "pmid": 28436599, "title": "Metformin as targeted treatment in fragile X syndrome.", "journal": "Clin Genet", "authors": ["Dy ABC", "Tassone F", "Eldeeb M", "Salcedo-Arellano MJ", "Tartaglia N", "Hagerman R"], "date": "2018-02-01T00:00:00Z", "doi": "10.1111/cge.13039", "meta_date_publication": "2018 Feb", "meta_volume": "93", "meta_issue": "2", "meta_pages": "216-222", "score": 50081.516, "text_hl": "@<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ as targeted treatment in @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@fragile X syndrome@@@.", "citations": {"NLM": "Dy ABC, Tassone F, Eldeeb M, Salcedo-Arellano MJ, Tartaglia N, Hagerman R. Metformin as targeted treatment in fragile X syndrome. Clin Genet. 2018 Feb;93(2):216-222. PMID: 28436599", "BibTeX": "@article{28436599, title={Metformin as targeted treatment in fragile X syndrome.}, author={Dy ABC and Tassone F and Eldeeb M and Salcedo-Arellano MJ and Tartaglia N and Hagerman R}, journal={Clin Genet}, volume={93}, number={2}, pages={216-222}}"}}, {"_id": "28676484", "pmid": 28676484, "title": "A therapy for FXS?", "journal": "Sci Signal", "authors": ["Ferrarelli LK"], "date": "2017-07-04T00:00:00Z", "doi": "10.1126/scisignal.aao2238", "meta_date_publication": "2017 Jul 4", "meta_volume": "10", "meta_issue": "486", "meta_pages": "", "score": 50079.6, "text_hl": "The antidiabetic drug @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ might be repurposed to treat @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Fragile_X_Syndrome</m> @DISEASE_MESH:D005600 @@@fragile X syndrome@@@.", "citations": {"NLM": "Ferrarelli LK. A therapy for FXS? Sci Signal. 2017 Jul 4;10(486):. PMID: 28676484", "BibTeX": "@article{28676484, title={A therapy for FXS?}, author={Ferrarelli LK}, journal={Sci Signal}, volume={10}, number={486}}"}}]}